Dr. Athena Countouriotis became president and chief executive officer and was named to the Turning Point Therapeutics board of directors in September 2018. She has broad oncology biotech leadership experience, guiding multiple development programs to approval. Her experience includes large and small molecule therapeutics in hematologic and solid tumor indications, with multiple regulatory approvals in the U.S. and Europe.
She joined Turning Point Therapeutics in May 2018 as executive vice president and chief medical officer to advance the clinical development of repotrectinib. She previously served as senior vice president and chief medical officer for Adverum Biotechnologies, and before that as senior vice president and chief medical officer of Halozyme Therapeutics. Dr. Countouriotis also served as chief medical officer of Ambit Biosciences, where she helped lead the company’s initial public offering and was responsible for the clinical development of quizartinib until the company’s acquisition by Daiichi Sankyo in November 2014. Earlier in her career, Dr. Countouriotis led various clinical development organizations within Pfizer and Bristol-Myers Squibb for oncology therapeutics including Sutent ®, Mylotarg ™, Bosulif ® and Sprycel ®.
Dr. Countouriotis also serves on the board of directors of Iovance Biotherapeutics and Passage Bio. She earned a Bachelor of Science degree from the University of California, Los Angeles, and an M.D. from Tufts University School of Medicine. She received her initial medical training in pediatrics at the University of California, Los Angeles, and additional training at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology/Oncology Program.